Robeco Institutional Asset Management B.V. Sells 160,519 Shares of Insulet Corporation $PODD

Robeco Institutional Asset Management B.V. lessened its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 93.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 12,010 shares of the medical instruments supplier’s stock after selling 160,519 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Insulet were worth $1,567,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. State of Wyoming boosted its stake in shares of Insulet by 34.6% in the first quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock valued at $60,000 after purchasing an additional 73 shares during the period. Optas LLC grew its holdings in shares of Insulet by 8.8% in the first quarter. Optas LLC now owns 1,059 shares of the medical instruments supplier’s stock valued at $222,000 after purchasing an additional 86 shares in the last quarter. American Trust increased its stake in Insulet by 8.6% during the 1st quarter. American Trust now owns 1,180 shares of the medical instruments supplier’s stock worth $248,000 after buying an additional 93 shares during the period. Basecamp Wealth Advisors LLC increased its stake in Insulet by 48.3% during the 1st quarter. Basecamp Wealth Advisors LLC now owns 313 shares of the medical instruments supplier’s stock worth $66,000 after buying an additional 102 shares during the period. Finally, Elevation Wealth Partners LLC increased its stake in Insulet by 115.6% during the 3rd quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 104 shares during the period.

Insulet Stock Performance

Shares of Insulet stock opened at $149.26 on Tuesday. The business has a 50-day simple moving average of $140.62 and a 200-day simple moving average of $182.66. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. Insulet Corporation has a one year low of $126.40 and a one year high of $354.88. The company has a market cap of $10.35 billion, a PE ratio of 27.90, a P/E/G ratio of 1.17 and a beta of 1.11.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.19. The firm had revenue of $801.70 million for the quarter, compared to analysts’ expectations of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm’s revenue was up 23.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, equities research analysts forecast that Insulet Corporation will post 6.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on PODD shares. Evercore set a $180.00 target price on shares of Insulet in a report on Monday, July 6th. Sanford C. Bernstein dropped their price target on shares of Insulet from $200.00 to $175.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Benchmark dropped their price target on shares of Insulet from $250.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Raymond James Financial reaffirmed an “outperform” rating and set a $180.00 price objective on shares of Insulet in a research report on Thursday, August 6th. Finally, Robert W. Baird set a $175.00 price objective on Insulet in a research report on Thursday, August 6th. Thirteen investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $186.68.

Insulet Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.